Recent investigations have centered on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopamine signaling. While GCGR activators are commonly employed for addressing type 2 diabetes, their unexpected effects on reinforcement circuits, specifically mediated by DA networks,